Thematic scorecard update: UCB and Samsung Bioepis’ artificial intelligence scores increase after recent partnerships
The artificial intelligence (AI) scores for UCB and Samsung Bioepis have been updated on GlobalData’s Drug Development Thematic Scorecard as a result of new partnerships.
UCB: Score Increased from 3 to 4
On 23 February, UCB announced it had expanded an existing collaboration with Microsoft to use the latter’s AI, Cloud, and computational services to support its discovery of new immunology and neurology drugs more quickly and efficiently. The collaboration aims to use data insights to improve the patient journey and the impact of treatments, enable faster drug discovery, and accelerate clinical development timelines. UCB and Microsoft previously partnered on the global, open-science COVID Moonshot project, where UCB’s chemists contributed potent compound designs to create an oral Covid-19 anti-viral.
Samsung Bioepis: Score Increased from 1 to 3
On 18 January, a new partnership was announced between Samsung Bioepis and o9 Solutions, where Samsung Bioepis will use the latter’s AI-powered integrated business planning platform to strengthen the management and planning of its biopharmaceutical manufacturing and supply chain distribution, as well as enhance its focus on R&D, clinical trials, and regulatory activities. The partnership will use AI and analytics to support Samsung Bioepis by enhancing productivity and reducing costs.
GlobalData’s Drug Development thematic scorecard provides a comprehensive outlook for players in the drug development sector over the next two to four years, based on ten of the major themes set to transform the landscape, including AI. It includes 55 companies from across the industry, including biopharmaceutical companies, biosimilar and generic manufacturers, contract development and manufacturing organisations, and contract research organisations. Using GlobalData’s core datasets such as sales forecasts and deals, companies are scored on a scale of 1 to 5, where 1 is vulnerable and 5 is dominant.
AI can be used for faster drug discovery and repurposing, enhanced clinical trial design and recruitment, smarter supply chains, and targeted and personalised sales and marketing tactics. There has been increased activity from the pharma industry in the AI space over the past few years. For example, there were just four partnerships for AI-based drug discovery forged by Big Pharma in 2015. By 2019, this had increased to 27 partnerships. The importance of AI to the pharmaceutical industry was highlighted in GlobalData’s recent ‘Digital Transformation and Emerging Technology in the Healthcare Industry’ survey, where respondents indicated that AI will be a key area of investment over the next two years and will also be the leading disrupting technology.